ArticleMolecular brain2026
Hippocampal transcriptome profiling in a 22q11.2 deletion syndrome mouse model: comparison with human schizophrenia.
Article in Molecular brain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
22q11.2 deletion syndrome (22q11.2DS) confers one of the highest genetic risks for schizophrenia, yet the molecular mechanisms remain incompletely understood. We performed comprehensive RNA sequencing of the dorsal hippocampus in Df1/+ mice, a 22q11.2DS model, integrating behavioral assessment and cross-species comparison with human schizophrenia postmortem data. Df1/+ mice exhibited selective contextual fear memory impairment without gross locomotor deficits. Transcriptomic analysis using integrated over-representation and gene set enrichment approaches revealed upregulation of synaptic signaling pathways, including glutamatergic and GABAergic neurotransmission, alongside downregulation of translational machinery and ribosomal proteins. Top upregulated pathways included "regulation of postsynaptic membrane potential" and "postsynapse organization," featuring glutamatergic receptors, voltage-gated channels, and synaptic adhesion molecules. Downregulated pathways centered on protein synthesis, including cytoplasmic translation and ribosome biogenesis. Cross-species comparison with human schizophrenia hippocampus revealed limited but directionally consistent gene-level overlap, with 21 of 23 shared differentially expressed genes showing concordant regulation. "Regulation of postsynaptic membrane potential" was the pathway significantly enriched across both species and analytical methods, encompassing both excitatory and inhibitory receptor subunits and synaptic regulators. Concordantly downregulated genes spanned glial markers and extracellular matrix components. These findings reveal a molecular signature of enhanced synaptic gene expression coupled with reduced translational capacity and glial support, with cross-species correspondence supporting the model's translational relevance and highlighting excitatory-inhibitory imbalance as a shared mechanism in hippocampal dysfunction underlying schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.